News & Perspective
Drugs & Diseases
CME & Education
Video
Decision Point
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      News & Perspective Drugs & Diseases CME & Education Video Decision Point
      Drugs & Diseases > Neurology

      Congenital Muscular Dystrophy

      Updated: Jul 03, 2019
      • Author: Emad R Noor, MBChB; Chief Editor: Stephen L Nelson, Jr, MD, PhD, FAACPDM, FAAN, FAAP, FANA  more...
      • Print
      Overview

      Background

      Congenital muscular dystrophies (CMDs) are extremely rare and greatly heterogeneous neuromuscular disorders with onset at birth or early infancy, characterized by hypotonia, delayed motor development, and progressive weakness. The clinical presentation is variable and can affect other organs, including the eyes, brain, lungs, and heart. Serum creatine kinase (CK) is elevated in several cases but not all. Appropriate muscle biopsy studies are crucial for accurate diagnosis.

      In 1903, Batten described 3 children who had proximal muscle weakness from birth. Biopsy of their muscles showed evidence of chronic myopathy without distinguishing characteristics. In 1908, Howard coined the term congenital muscular dystrophy (CMD) when he described another infant with similar features. Ullrich first described the combination of joint hyperlaxity and proximal contractures in 1930 in the German literature; this was the first case of what is now known as Ullrich congenital muscular dystrophy.

      In 1960, Fukuyama et al described a common congenital muscular dystrophy in Japan that always had features of muscular dystrophy and brain pathology. [1] Other diseases involving the muscle, eye, and brain were subsequently described: a Finnish variant (originally called muscle-eye-brain disease and Walker-Warburg syndrome. As has become clear with molecular genetics, all of these CMDs are likely caused by a similar molecular pathologic event, abnormal glycosylation of α-dystroglycan.

      In a study of 116 patients in the United Kingdom, the most common congenital muscular dystrophies were collagen VI-related disorders (19%), with α-dystroglycanopathy congenital muscular dystrophy (12%) and merosin-deficient congenital muscular dystrophy (MDC1A) (10%) being next in frequency. An Australian study in 2008 showed dystroglycanopathy as the most common congenital muscular dystrophy (25%) on that continent, followed by collagen VI-related disorders (12%). Fukuyama congenital muscular dystrophy is the most prevalent form (49.2%) in Japan, followed by collagen VI deficiency at 7.2%. [1]

      In general, CMDs are autosomal recessive diseases resulting in severe proximal weakness at birth (or within the first 12 mo of life) that is either slowly progressive or nonprogressive. Contractures are common, and CNS abnormalities can occur. Muscle biopsy shows signs of dystrophy, including a marked increase in endomysial and perimysial connective tissue; variability in fiber size with small, round fibers; immature muscle fibers; and (uncommonly) necrotic muscle fibers. No distinguishing features are present in muscle biopsy specimens, differentiating these disorders from the congenital myopathies.

      Classifications of congenital muscular dystrophy

      Several authors of review articles have proposed classifications for the congenital muscular dystrophies. Recent classification schemes follow the following pattern: [2, 3]

      Defects of structural proteins

      • Merosin deficient CMD (MDC1A); Lamininα2, Gene LAMA 2 (6q22-q23)

      • UCMD1; Collagen 6A1

      • UCMD2; Collagen 6A2

      • UCMD3; Collagen 6A3

      • Integrin α7-deficient CMD; Integrin α7

      • CMD with epidermolysis bullosa; Plectin

      Defects of glycosylation

      • Walker-Walburg syndrome; multiple genes

      • Muscle-eye brain disease, multiple genes

      • Fukuyama CMD; Fukutin

      • Other phenotypes associated with mutations in glycosyltransferase genes

      Proteins of the endoplasmic reticulum and nucleus

      • Rigid spine syndrome; Selenoprotein N, 1

      • Rigid spine syndrome; Selenocysteine insertion sequence-binding protein 2

      • LMNA-deficient CMD; Laminin A/C

      Mitochondrial membrane protein

      • CMD with mitochondrial structural abnormalities; Choline kinase beta

      The OMIM classification of defects of glycosylation is as follows:

      • Muscular dystrophy-dystroglycanopathy A1 (MDDGA1 ) – POMT1 mutation

      • MDDGA2 – POMT2 mutation

      • MDDGA3 – POMGNT1 mutation

      • MDDGA4 – Fukutin mutation

      • MDDGA5 – FKRP mutation

      • MDDGA6 – LARGE mutation

      • MDDGA7 – ISPD mutation

      • MDDGA8 – GTDC2 mutation

      • MDDGA10 – TMEM5 mutation

      • MDDGA11 – G3GALNT2 mutation

      • MDDGA12 – SGK196 mutation

      • MDDGA – B3GNT1 mutation

      Genetic features

      Only the muscular dystrophies with known genetic mutations are discussed in more detail later in this article. Several rare forms of congenital muscular dystrophy are not discussed in this article because of the lack of precise molecular and/or genetic information. The diagnosis of congenital muscular dystrophy is now based on clinical findings, muscle biopsy results, and genetic information.

      Next:

      Pathophysiology

      The pathophysiology of the congenital muscular dystrophies depends on the specific genetic defect for each of the dystrophies and is discussed with each of the congenital muscular dystrophies below.

      Previous
      Next:

      Epidemiology

      Frequency

      An Italian study identified mutations in 220 of 336 patients (65.5%). The most common forms of CMD were those with α-dystroglycan glycosylation deficiency (40.18%) followed by those with laminin α2 deficiency (24.11%) and collagen VI deficiency (20.24%). The forms of CMD dystrophy related to mutations in SEPN1 and LMNA were less frequent (6.25% and 5.95%, respectively). [4]

      In Japan, Fukuyama congenital muscular dystrophy is fairly common. It is approximately 50% as common as Duchenne muscular dystrophy. The estimated prevalence is approximately 7–12 cases per 100,000 children. [1] In Italy, the prevalence of all congenital muscular dystrophies has been estimated to be 4.7 cases per 100,000 children, while in Sweden the incidence is estimated at 6.3 cases per 100,000 births. Only about 25–50% of patients with CMD have an identifiable genetic mutation. [2]

      The prevalence and incidence of the congenital muscular dystrophies varies in different regions of the world. For example, in a study of 116 patients in the United Kingdom, the most common congenital muscular dystrophies were collagen VI–related disorders (19%), with α-dystroglycanopathy congenital muscular dystrophy (12%) and merosin-deficient congenital muscular dystrophy (MDC1A) (10%) being next in frequency. [5] The Australian study by Peat and colleagues in 2008 [6] showed dystroglycanopathy as the most common congenital muscular dystrophy (25%) on that continent, followed by collagen VI–related disorders (12%). Fukuyama congenital muscular dystrophy is the most prevalent form (49.2%) in Japan, followed by collagen VI deficiency at 7.2%. [7]

      Mortality/Morbidity

      Morbidity and mortality rates depend on the type of congenital muscular dystrophy.

      The major causes of morbidity and mortality are related to respiratory insufficiency, bulbar and limb weakness, contractures, seizures, ocular pathology, and intellectual disability and associated brain pathology.

      Some children die in infancy, whereas others can live into adulthood with only minimal disability.

      Demographics

      These autosomal recessive diseases affect both sexes equally.

      Patients with congenital muscular dystrophy present at birth or within the first year of life.

      Previous
      Next:

      Prognosis

      The prognosis depends on the type of congenital muscular dystrophy (CMD).

      With severe disease, such as Walker-Warburg syndrome, patients usually die within the first few years of life.

      In congenital muscular dystrophy with laminin-α2 deficiency and in some cases of mutations in FKRP, patients occasionally have a relatively normal life span.

      Previous
      Next:

      Patient Education

      Genetic counseling is often helpful to patients and their families to assist in family planning.

      Previous
      Clinical Presentation
       
       
      Media Gallery
      of 1
      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Manage Preferences Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
      Editions
      English Deutsch Español Français Português UK
      All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.